Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does POMALIDOMIDE Cause Upper respiratory tract infection? 439 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 439 reports of Upper respiratory tract infection have been filed in association with POMALIDOMIDE (Pomalyst). This represents 0.5% of all adverse event reports for POMALIDOMIDE.

439
Reports of Upper respiratory tract infection with POMALIDOMIDE
0.5%
of all POMALIDOMIDE reports
23
Deaths
141
Hospitalizations

How Dangerous Is Upper respiratory tract infection From POMALIDOMIDE?

Of the 439 reports, 23 (5.2%) resulted in death, 141 (32.1%) required hospitalization, and 9 (2.1%) were considered life-threatening.

Is Upper respiratory tract infection Listed in the Official Label?

Yes, Upper respiratory tract infection is listed as a known adverse reaction in the official FDA drug label for POMALIDOMIDE.

What Other Side Effects Does POMALIDOMIDE Cause?

Plasma cell myeloma (7,023) Death (6,795) Fatigue (6,530) Pneumonia (5,792) Off label use (3,845) Diarrhoea (3,351) White blood cell count decreased (3,328) Neutropenia (3,029) Rash (2,715) Dyspnoea (2,543)

What Other Drugs Cause Upper respiratory tract infection?

ADALIMUMAB (3,306) ETANERCEPT (2,948) TOFACITINIB (1,805) RITUXIMAB (1,713) ABATACEPT (1,623) METHOTREXATE (1,576) TOCILIZUMAB (1,455) APREMILAST (1,437) PREDNISONE (1,354) SECUKINUMAB (1,339)

Which POMALIDOMIDE Alternatives Have Lower Upper respiratory tract infection Risk?

POMALIDOMIDE vs POMALYST POMALIDOMIDE vs PONATINIB POMALIDOMIDE vs PONATINIB\PONATINIB POMALIDOMIDE vs PONESIMOD POMALIDOMIDE vs PORACTANT ALFA

Related Pages

POMALIDOMIDE Full Profile All Upper respiratory tract infection Reports All Drugs Causing Upper respiratory tract infection POMALIDOMIDE Demographics